LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
XCUR
Exicure, Inc.
There isn't enough reported data to score XCUR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XCUR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
XCUR's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XCUR PE Valuation
XCUR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
XCUR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect XCUR's losses to grow, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over XCUR on earnings quality, reporting a profit while its opponent remains loss making.
XCUR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.34 | +$2.48 |
| Q1 2026 | -$1.57 | +$2.19 |
| Q4 2025 | -$0.79 | +$3.96 |
| Q3 2025 | -$3.64 | -$1.62 |
| Q2 2025 | -$3.82 | +$0.68 |
| Q1 2025 | -$3.76 | +$3.79 |
| Q4 2024 | -$4.75 | +$5.80 |
| Q3 2024 | -$2.02 | -118% |
XCUR is still losing money, but far less than before: $1.34 per share over the past year, against $82.50 at its worst in mid-2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over XCUR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
XCUR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $21.8M | +928% |
| Q2 2022 | $2.5M | +3028% |
| Q1 2022 | $2.6M | +157% |
| Q4 2021 | $2.1M | +1413% |
| Q2 2021 | $79K | -98% |
| Q1 2021 | $997K | -89% |
| Q4 2020 | $140K | -55% |
| Q3 2020 | $2.4M | +364% |
XCUR's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2024 | -167% | N/A |
| Q4 2022 | 85% | +720 points |
| Q3 2022 | -258% | N/A |
| Q2 2022 | -303% | +17244 points |
| Q1 2022 | -302% | +918 points |
| Q4 2021 | -635% | +8265 points |
| Q2 2021 | -17547% | -17456 points |
| Q1 2021 | -1219% | -1225 points |
XCUR's operating margin was −167% last quarter, up 134 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with XCUR at up 68%.
XCUR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.1M | +$456K |
| Q4 2025 | -$934K | -$89K |
| Q3 2025 | -$3.4M | -$3M |
| Q1 2025 | -$1.6M | -$1.1M |
| Q4 2024 | -$845K | -$29K |
| Q3 2024 | -$449K | +$963K |
| Q2 2024 | -$1.2M | +$3.6M |
| Q1 2024 | -$450K | +$2.9M |
XCUR has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XCUR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XCUR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +25 shares |
| 1 year | +0.9% | +56.2K shares |
| 3 years | +278% | +4.7M shares |
| 5 years | +996% | +5.8M shares |
| Available history | +1379% | +5.9M shares |
XCUR has 6M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | $9,000 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
XCUR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.2x | Net Cash |
| Q2 2023 | -0.6x | Net Cash |
| Q1 2023 | -4.0x | Net Cash |
XCUR has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XCUR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.4 | Neutral |
| Stochastic | 20.3 | Neutral |
XCUR's weekly RSI is 31 (neutral) and its Stochastic is 20 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XCUR PE vs Healthcare Sector
| Metric | XCUR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XCUR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over XCUR on trend strength, trading above more of its moving averages.
XCUR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.08 | 1.9% below |
| 20 week MA | $1.31 | 19% below |
| 50 week MA | $3.02 | 65% below |
| 100 week MA | $5.82 | 82% below |
| 200 week MA | $5.12 | 79% below |
XCUR is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over XCUR on returns for 2026, with the stronger performance.
XCUR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $417.0 | $289.5 | -31% |
| 2021 | $289.5 | $32.6 | -89% |
| 2022 | $32.6 | $6.40 | -80% |
| 2023 | $6.40 | $2.90 | -55% |
| 2024 | $2.90 | $17.6 | +506% |
| 2025 | $17.6 | $5.99 | -66% |
| 2026 YTD | $5.99 | $1.06 | -82% |
XCUR's yearly returns have swung widely, from +506% in 2024 to −89% in 2021. It's down 82% so far in 2026.